Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URANIA: Neoadjuvant weekly utidelone + cisplatin in high‑risk early/locally advanced breast cancer
ChiCTR2400084686Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of utidelone in breast cancer (2 cohorts), sponsored by Renji Hospital. Primary endpoint: Pathologic complete response (breast and axillary). Planned start May 2024; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400084686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084686.